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Renal mass and reserve of vitamin D: Determinants in primary
hyperparathyroidism. We studied circulating 1 ,25(OH)2D3 and its de-
terminants in 102 patients with primary hyperparathyroidism (PHPT),
33 of them with recurrent renal stones, 60 with non-specific symptoms,
and nine with overt bone disease. Means for serum I ,25(OH)2D3 and
intestinal absorption of calcium were abnormally high in the renal stone
group, slightly elevated in the non-specific group, and low—normal in
the bone disease group. In the whole population of patients, we found
a positive correlation between circulating 1 ,25(OH)2D3 and creatinine
clearance (taken as an index of the functional renal mass). Negative
correlations were observed between 1 ,25(OH)2D3 and age, and between
creatinine clearance and age, the latter being not different from that
observed in a normal large population. In the renal stone group, means
for the determinants of the renal 1 alpha hydroxylase activity, that is,
PTH activity expressed as nephrogenous cyclic AMP (NcAMP), serum
phosphate and calcium were identical to those of the group with
non-specific symptoms. However means for age were lower and func-
tional renal mass significantly higher in the renal stone group, which
may account for the higher value of circulating 1 ,25(OH)2D3. In the
bone disease group, means for age, renal mass and serum calcium were
identical to those of the group with non-specific symptoms, and
NcAMP was far higher and hypophosphatemia more marked, which
may not account for the lower value of circulating l,25(OH)2D3.
However, in the bone disease group, serum 25(OH)D was abnormally
low, which may limit the renal production of I ,25(OH)2D3 and explain
the low—normal circulating values. From these results, we suggest that
the renal mass and vitamin D reserve might be two major determinants
of the circulating values of 1,25(Oh)2D,, and of the clinical presentation
of PHPT. In young patients with high renal mass, PTH hypersecretion
would result in a very large production of 1 ,25(OH)2D3, and thus very
high intestinal absorption of calcium, hypercalciuria and high risk of
renal stones. In older patients, with lower renal mass and normal
reserve of vitamin D, a similar degree of PTH hypersecretion would
result in a slightly elevated I ,25(OH)2D,, and thus high—normal intesti-
nal absorption of calcium and calciuria, and low risk of renal stones. In
older patients with vitamin D deficiency, the low—normal l,25(OH)2D,,
low intestinal absorption of calcium, and far higher degree of PTH
hypersecretion may explain the occurrence of overt bone disease.
Patients with primary hyperparathyroidism (PHPT) are gen-
erally classified into three main groups: those with renal stones,
those with bone disease, and those with non-specific symptoms.
Patients presenting with stone disease rarely display evidence
of overt osteitis; and patients presenting with clinical bone
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disease only rarely have an history of renal stones [1]. Patients
with asymptomatic PHPT do not seem to exhibit renal stone or
overt bone disease for a period of 10 years [2]. These descrip-
tive differences are difficult to explain on the basis of the unique
primitive abnormality of PHPT, that is, the chronic hypersecre-
tion of PTH. Thus the circulating level of 1 ,25(OH)2D3, which
controls the intestinal absorption of calcium, and which may be
influenced by numerous factors other than PTH, such as serum
phosphorus and calcium, 25(OH)D, renal functional mass and
age, might play a role in the clinical presentation of PHPT. In
one report, higher circulating values of 1 ,25(OH)2D3 were found
in patients with abnormally—high intestinal absorption of cal-
cium and high incidence of renal stones [3]. However, why
certain patients have normal or near—normal levels of
1,25(OH)2D3 while others have marked elevations in the circu-
lating levels of the active metabolite remains unexplained, as
recently underscored [4]. In two other reports, no differences in
serum 1 ,25(OH)2D3 were found between patients with and
without renal stones [5, 6]. Moreover the bone disease presen-
tation of PHPT is not clearly defined. From isolated reports,
vitamin D deficiency has been suggested to contribute to the
development of bone disease in PHPT [7, 8]. Measurements of
intestinal calcium absorption and circulating levels of
1,25(OH)2D3 in patients specifically defined as having osteitis
fibrosa cystica have not been reported as recently stressed [4].
The present investigation was designed: 1) to study serum
1 ,25(OH)2D3 and its determinants in a large population of
patients with PHPT; 2) to assess serum 1,25(OH)2D3 and its
determinants in well—defined PHPT subpopulations, that is,
subjects with renal stones, non-specific symptoms, or bone
disease; and 3) to attempt to establish the respective role of the
hypersecretion of PTH and circulating levels of 1 ,25(OH)2D3 in
determining the clinical presentation of the disease.
Methods
Three hundred and six patients were studied with the same
protocol, and a plasma sample of each patient was stored at
—30°C. These patients represented all the patients with
surgically—proven primary hyperparathyroidism who were eval-
uated in our unit during the past five years. Among these
patients, 102 were randomly sampled and thus were repre-
sentative of the whole population. There were 33 men and 69
women, with an average age of 54 17 years (range 18 to 82).
Surgical exploration revealed a single adenoma in 94 patients
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and primary hyperplasia in eight. Thirty—three patients (32%)
had a history of renal stones, with an average number of 0.63
stone per patient—year; sixty patients (59%) had non-specific
symptoms and their disease was discovered through routine
analysis of serum calcium; nine patients (9%) had severe bone
disease with radiographic evidence of osteitis fibrosa cystica
(widespread subperiosteal bone resorption, and brown tumors),
generalized osteopenia with diffuse bone pain and serum alka-
line phosphatases at more than five times the upper limit of
normal. The estimated minimal duration of the disease was. 3.3
3.7 years (range one month to 15 years) in the patients with
renal stones, and 0.8 0.7 year (range one month to 2 years) in
those with overt bone disease. Seasonal distribution of the
patients was similar to all three groups, so that potential
differences in serum 25(OH)D could not be related to seasonal
fluctuations. Informed consent was obtained from all patients
explored.
The investigation was performed as previously described [9].
During the days before the tests, patients were given normal
hospital diet. Meals taken the day before testing were poor in
calcium, that is, without cheese or dairy products, and virtually
calcium—free drinking water was given (<10 mg/liter of elemen-
tal calcium). From after dinner on the evening before the tests,
patients fasted until the investigation, which started next morn-
ing at 8:30 a.m. and lasted for half a day. During the tests,
patients were given virtually calcium—free drinking water in
sufficient quantities to yield adequate urine specimens. Two or
three urine collections lasting for 30 to 45 minutes each were
made in the basal state, with patients fasting, and in the middle
of each collection period, blood was sampled without tourni-
quets, through a catheter inserted into a large vein of the arm.
An oral load of 1 g of elemental calcium was then administered
and two more timed urine collections were made, covering the
second and third hours after calcium loading, with blood
sampling in the middle of each period.
The following parameters were measured: calcium, inorganic
phosphorus, creatinine, and cAMP for all blood samples, and,
for the first blood sample only, iPTH, 25(OH)D, 1 ,25(OH)2D3.
Calcium, phosphorus, creatinine, and cAMP were measured in
each urine sample. Serum total calcium was determined by
titration with EGTA (Corning 940), serum ionized calcium by
specific electrode (Orion), creatinine by colorimetric method
(picric acid), inorganic phosphorus by molybdate, and cAMP
by radiocompetition on a protein, using a modified version of
Gilman's method [101, with tritiated cAMP as tracer; cAMP
was extracted from plasma with ethanol (extraction yield: 90 to
98%), and plasma and urine cAMP were determined in samples
collected on EDTA [9]. PTH was measured by a commercially
available parathyroid radioimmunoassay system using antibody
detecting the carboxy-terminal fragment 53-84 of human syn-
thetic PTH (HPTH-C-K, CIS-CEA, Saclay, France). The
bound and free fractions of 1251-PTH were separated with a
second antibody (sheep gammaglobulin antiserum). Serum
25(OH)D was measured by the technique of Preece et al [111.
Serum 1 ,25(OH)2D3 was measured by the technique of Bouillon
et al [12]. Tritiated 1 ,25(OH)2D3 was obtained from Amersham
International (England). Intra-assay variation was 11.8% (N =
11) and during the measurement of the 102 patients' plasma
samples, the inter-assay fluctuation was 12%. The normal
value, mean value SD, is 101 36 pmollliter (42 15 pg/mi,
Table 1. Subpopulations of patients with PHPT
Calciuria
response to
oral load of Fasting
Groups of Sex 1 ,25(OH)2D3 1 g calcium calciuria
patients F/M pmol/liter pinol/di GF pjnol/dl GF
I Renal stone 17/16 222C 7.04c 4.81c
N = 33
P value (I vs. II) <0.001 <0.001 NS
II Non specific
symptoms 46/14 157b 4.00 5.03cN = 60
P value (H vs. III) <0.01 <0.05 NS
III Bone disease 8/1 83 077" 704C
N = 9
P value (HI vs. I) <0.001 <0.001 NS
Normal subjects 101 3.8 1.75
N = 40 (N=18)
Values are means SD
b.c Indication of the significance of the differences between values for
a group and values for the normal subjects; b P < 0.05; P < 0.001
N = 18). Calculated parameters were the following: glomerular
filtration rate (GFR), estimated from endogenous creatinine
clearance, and expressed in mllmin, fasting calciuria, expressed
in mol/dl GF inorganic phosphorus Tm, expressed in
mmollliter glomerular filtrate (TmPi/GF) and calculated using
the Bijvoët diagram [13], and nephrogenous cyclic AMP
(NcAMP), expressed in nmolldl GF as described previously [9,
141. Intestinal calcium absorption was assessed from the rise in
calciuria (mol/dl GF) during the second and third hours after
oral loading of 1 g elemental calcium [15].
Normal ranges (means 2 SD in our laboratory) are, for
serum calcium, 2.17 to 2.57 mmol!liter (87 to 103 mg/liter),
serum ionized calcium, 2.16 to 2.52 mEq/liter, serum phospho-
rus, 0.77 to 1.36 mmol/liter (24 to 42 mg/liter), TmPi, 0.77 to
1.45 mmollliter GF (24 to 45 mg/liter GF), NcAMP, 0.5 to 2.0
nmol/dl GF, serum iPTH, <76 pg/ml, and serum 25(OH)D, 14 to
96 nmollliter (5.6 to 38 ng/Iiter). Means 2 SD are, for fasting
calciuria, 0.25 to 3.25 mol/dl GF (0.1 to 1.3 mg/liter GF) and
for increase in calciuria after oral load, 2.4 to 5.2 molIdl GF (1
to 2.2 mg/liter GF).
The results in the text, figures and tables are means 1 SD.
The statistical significance between two groups was tested by
two—tailed t-test after the analysis of variance demonstrated the
existence of difference between groups. When two groups
which did not differ were pooled to be compared to a third
group, Sheffe's test was used [16]. The comparison of values of
iPTH were made after logarithmic transformation [16]. The
differences between the linear correlations were tested by
analysis of covariance [16].
Results
Overall results and comparison of subpopulations of patients
with PHPT
The data are shown in Tables 1 and 2. Mean values for serum
1,25(OH)2D3 were abnormally high in patients with renal
stones, moderately elevated in patients with non-specific symp-
toms, and low—normal in those with overt bone disease. These
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Table 2. Values for the determinants of circulating I ,25(OH)2D3 in the subpopulations of patients with primary hyperparathyroidism
25 (OH)D NcAMP iPTH
Serum
phosphorus TmPiIGF
Serum calcium
GFR AgeTotal Ionized
Groups of patients nmoi/liter nmoi/di GF pg/mi mmol/liter mmoi/liter mmol/liter mEqiliter ml/min/1.73m2 years
I Renal stone 44 42" 110 0.73" 0b 281b 294b 113 41
N = 33 ±34 ±1.8 ±113 ±0.13 ±0.14 ±0.25 ±0.31 ±31 ±14
P value (I vs. II) <0.05 NS NS NS NS NS NS <0.001 <0.001
H Non-specific symptoms 28 4.2" 119 0.76" 0.63" 281b 289b 87 59N = 60 ±22 ±1.5 ±90 ±0.15 ±0.18 ±0.25 ±0.31 ±28 ±15
P value (H vs. III) <0.05 <0.001 <0.001 <0.01 <0.05 NS NS NS MS
III Bone disease 8.5a 120b 328 060b 0.46" 289b 312b 84 62
N = 9 ±4.9 ±5.5 ±211 ±0.18 ±0.18 ±0.47 ±0.51 ±45 ±13
P value (III vs. I) <0.001 <0.001 <0.001 <0.05 <0.05 NS NS <0.01 <0.001
Normal subjects 33 1.28 <76 1.06 1.11 2.37 2.34
N = 40 ±9 ±0.34 ±0.14 ±0.17 ±0.10 ±0.09
Values are means ± SD
a,b Indicate the significance of the differences between values for a group, and values for the normal subjects; a P < 0.01; "P < 0.001
values differed significantly in the three groups. Means for
serum 25(OH)D were normal in patients with renal stones and
nonspecific symptoms (although they were significantly higher
in patients with renal stones), and abnormally low in patients
with bone disease. Each mean value was significantly different
from the others. The rises in NcAMP and serum iPTH were
similar in patients with renal stones and non-specific symptoms,
but far larger in those with bone disease (note the overlap with
normal values for iPTH). Means for serum phosphorus and
TmPiJGF were low in all groups, and significantly lower in
patients with bone disease. No differences between groups
were observed for serum calcium (total calcium and ionized
forms), although the values tended to be higher in the bone
disease group. Mean gomerular filtration rates were similar in
patients with bone disease and non-specific symptoms, but
significantly higher in those with renal stones. Mean ages were
not different in patients with bone disease and non-specific
symptoms, but significantly lower in patients with renal stones.
Mean intestinal absorptions of calcium, estimated from the
increase in urinary calcium after the oral load of calcium, were
abnormally high in patients with renal stones, normal in patients
with non-specific symptoms, and low in patients with bone
disease. In addition, a positive linear correlation between serum
1 ,25(OH)2D3 (y, pmollliter) and intestinal absorption of calcium
(x, .tmol/dl GF) was noted in the whole population of patients (y
= 108 + 13.4 x, r 0.64, P < 0.001). Lastly, means for fasting
calciuria, taken as an index of net bone resorption, were
abnormally high in all patients, and higher (without reaching
significance) in the patients with bone disease.
Correlations between the levels of circulating 1 ,25(OH)2D3
and of its determinants in the whole population and in groups
of patients
In the whole population of patients, we found a direct linear
correlation between serum 1 ,25(OH)2D3 and the glomerular
filtration rate (Fig. 1) and an inverse correlation between serum
1 ,25(OH)2D3 and age (Fig. 2). An inverse linear correlation
between the glomerular filtration rate (y, mllmin/1 .73 m) and
age x, years) was also noted (Fig. 3). When the latter correlation
was compared to that found in our laboratory in 87 normal
subjects (age ranging from 17 to 86 years), the slopes and y
intercepts of the two relations were not significantly different
(Fig. 3). No linear correlation was noted in the whole popula-
tion of patients between serum 1 ,25(OH)2D3 on one hand, and
nephrogenous cyclic AMP, serum iPTH, serum 25(OH)D,
serum phosphorus or serum calcium on the other. The correla-
tion found between serum 1,25(OH)2D3 and GFR, which may
be considered as an index of functional renal mass, suggests
that renal mass is an important factor influencing the production
of 1 ,25(OH)2D3. We therefore explored possible correlations
between each determinant and 1 ,25(OH)2D3 values, expressed
as a function of GFR (that is, per unit of renal mass) to minimize
renal mass as a source of variation in 1 ,25(OH)2D3. In the whole
population of patients no correlation was noted between
1 ,25(OH)2D3/dl GF and its determinants. However in patients
with renal stones and those with non-specific symptoms, posi-
tive linear correlations were found between 1 ,25(OH)2D3/dl GF
and NcAMP with similar slopes and y intercepts. Therefore
data from these two groups were pooled (Fig. 4). It should be
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Fig. 1. Relationship between values for creatinine clearance and cir-
culating I,25(OH)2D3 in the entire population of PHPT. Symbols are:
(A) patients with renal stones; (A) non-specific symptoms; (•) bone
disease.
La
0
E0.
I0
CNJ
E
a(I)
: 1:1.07x
r = 0.66 P< 0.001
0•
. S
U-
0
E0.
I0
La
U.
5)
0
E0.
I0
La
],25(OH)2D3 and primary hyperparathyroidism 1177
400
350
300
250
200
150
100
50
y = 277.5-2.15x
N=102
r = 0.5 P < 0.001A
AA
A
A
U.
UU
AU U
A
UA
y = 78.3 + 28.4X
R = 0.49 P< 0.001
A N=92
0
0-•
0
I I j I I f
0
Nephrogenous cyclic AMP, rimol/100 ml GF
10 20 30 40 50 60 70 80 90 Fig. 4. Relationship between values for nephrogenous cyclic AMP and
Age, years 1,25(OH)2D3 expressed per 100 ml glomerular filtrate, in patients with
renal stones (A) and non-spec ffic symptoms (U). Note that for theFig. 2. Relationship between values for age and circulating patients with bone disease (0), these values were located below and to1,25(OH)2D3 in the entire population of PHPT. Symbols are: (A) the right of the regression line.patients with renal stones; () non-specific symptoms; (•) bone
disease.
y = 150-0.87x N = 87
• r = 0.61 P< 0.001
160
130
100
70
40
a
C.)C
a
C.)
aC
C
CSa0 $ Serum Pi mmol/liter
70
Age, years
Fig. 3. Relationship between values for age and creatinine clearance
in the entire population of PHPT. (•) patients with renal stones; (0)
non-specific symptoms; (•) bone disease. Note that the regression line
calculated for the normal subjects (. . .) is also shown.
noted that mean values for l,25(OH)2D3/dl GF were similar in
both groups (206 84 vs. 196 102). A negative linear
correlation between 1 ,25(OH)2D3/dl GF and serum phosphorus
was found when data of patients with renal stones and non
specific symptoms were pooled (Fig. 5). Finally we observed no
correlation between 1 ,25(OH)2D3/dl GF and serum calcium in
patients with renal stones and non specific symptoms. In the
group with bone disease, 1 ,25(OH)2D3/dl GF was not correlated
with NcAMP or serum phosphorus or calcium, and mean
l,25(OH)2D3/dl GF was significantly lower (124 63, P < 0.01)
than in the other groups, whereas NcAMP values were far
higher and hypophosphatemia more profound. Thus, serum
1 ,25(OH)2D3 per unit of renal mass was clearly not appropriate
to the degree of PTH hypersecretion (Fig. 4) and hypophos-
phatemia in the bone disease group. Moreover, in this group a
Fig. 5. Relationship between serum phosphorus and circulating
o 1,25(OH)2D3 expressed per 100 ml glomerular filtrate, in patients with
renal stones (A), and non-specific symptoms (U).
linear positive correlation was observed between serum values
of 25(OH)D (x, nmollliter) and 1 ,25(OH)2D3 (y, pmollliter),
y = 36.5 + 5.4 x, r = 0.75, P < 0.05.
Discussion
The main results of the present study are the following: 1) the
levels of circulating 1 ,25(OH)2D3 were abnormally high in the
renal stone presentation of PHPT, moderately increased in the
non specific presentation, and low—normal in the bone disease
presentation; 2) in patients with PHPT, the renal mass, which
normally decreases with age, and the reserve of vitamin D,
emerge as two important factors determining the circulating
levels of 1 ,25(OH)2D3; 3) when renal mass is taken into account,
PTH activity expressed as NcAMP, and to a lesser extent
serum phosphorus play a major role in regulating renal produc-
tion of 1 ,25(OH)2D3, provided that a sufficient reserve of the
substrate 25(OH)D is available.
In acute studies in vivo, the renal production of 1 ,25(OH)2D3
has been shown to depend on a number of factors which include
PTH, phosphate, calcium, age and GFR [17, 181. However, in
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Table 3. Features of absorptive and nonabsorptive patients with primary hyperparathyroidism
Category of
patients
Number of
patients
Sex
F/M
Number of
patients with
stones
Calciuric
response
mo1/d1 GF
I ,25(OH)2D3
pM
GFR
ml/min/1.73m2
Age
years
Absorptive 41 20/21 22/41 8.93 228 107 43
P value <0.01 <0.01 <0.001 <0.001 <0.001 <0.001
Nonabsorptivea 52 41/11 11/52 2.19 157 87 60
a Patients with osteitis fibrosa cystica were not included.
chronic disturbances in humans, the manner in which these
factors regulate the renal production of I ,25(OH)2D3 has yet to
be established, particularly in the presence of conflicting signals
as in PHPT. The direct linear correlation observed between
1 ,25(OH)2D3 and GFR in the whole population of patients is a
new finding of great interest, because it emphasizes importance
of the renal mass as a factor influencing the circulating levels of
1 ,25(OH)2D3 in PHPT. The correlations noted in the present
work between serum 1 ,25(OH)2D3 and age, and between GFR
and age similar to that observed in normal subjects, indicate
that the decrease in circulating 1 ,25(OH)2D3 with age in PHPT
is secondary to the progressive and physiological decline in
renal mass. In agreement with the role of renal mass are the
variations in serum 1,25(OH)2D3 observed in normal subjects,
in whom similar correlations were found between basal serum
1,25(OH)2D3 and age [18, 19], between 1,25(OH)2D3 and GFR
[181. The lack of correlation between serum 1 ,25(OH)2D3 and
the substrate 25(OH)D in the whole population might seem at
variance with a recent work showing a significant positive
correlation between serum concentration of 25(OH)D and
I ,25(OH)D3 after oral administration of 25(OH)2D3 in patients
with PHPT [20]. Our work does not rule out the possibility of a
substrate dependence of 1 ,25(OH)2D3 production in PHPT,
since the range of 25(OH)D values was smaller in the present
studies, 2.2 to 100 nM versus 15 to 450 flM.
Among other determinants, PTH activity, expressed as
NcAMP, and to a lesser extent serum phosphorus emerge as
determinants of 1 ,25(OH)2D3 renal production in PHPT, when a
sufficient store of vitamin D is available and the renal mass is
taken into consideration. To our knowledge, this is the first time
a direct correlation has been found in patients with PHPT
between an index of PTH secretion (NcAMP) and circulating
,25(OH)D3 expressed per unit of renal mass. This is in
agreement with earlier experimental results showing that PTH
stimulates 1 alpha hydroxylase activity, and that this stimula-
tion is mediated by cAMP [21, 22]. The absence of correlation
noted in a previous study [23] between serum 1 ,25(OH)2D3 and
urinary excretion of cAMP in PHPT is not surprising since the
number of patients studied was small, and urinary cAMP was
used as the index of PTH activity and not the cAMP added to
the urine by renal tubule [231. It should be noted that in the
present work no correlation was found between 1 ,25(OH)2D3
per unit of renal mass and serum iPTH (C terminal fragment),
probably because of the accumulation of biologically—inactive C
terminal fragments when the glomerular filtration rate declined.
This is in agreement with several previous investigations in
which no correlation was found between 1,25(OH)2D3 and
serum iPTH [23, 24]. The previously documented role of serum
phosphorus as a determinant of 1 ,25(OH)2D3 production [19,
24] was emphasized in the present work by the inverse corre-
lation observed between 1 ,25(OH)2D3 per unit of renal mass and
serum phosphorus, in the patients with renal stones and non-
specific symptoms. Lastly, serum calcium does not seem to
markedly influence the 1 ,25(OH)2D3 renal production, since no
correlation was found between 1 ,25(OH)2D3 per unit of renal
mass and either serum total or ionized calcium. Our observa-
tions seem to be at variance with a recent study, suggesting a
major role of calcium in experimental hyperparathyroidism
obtained by continuous i.v. PTH infusion for 12 days in dogs
and humans [25]. More prolonged experimental models will be
of great importance to resolve this issue.
In the present study, we confirm the difference in the circu-
lating levels of 1 ,25(OH)2D3 observed by Broadus et a! between
the absorptive and non-absorptive presentations of PHPT [3].
The intestinal absorption of calcium and circulating
l,25(OH)2D3 levels were high in the renal stone presentation,
and normal in the non-specific form (the normal intestinal
absorption of calcium in face of a moderately elevated serum
1 ,25(OH)2D3 may be explained by an increase in the blood—to—
lumen flux of calcium due to hypercalcemia). However, unlike
Broadus's results, our data strongly suggest for the first time
that differences in renal masses may explain the differences in
circulating 1,25(OH)2D3 levels. PTH activity reflected by
NcAMP and serum phosphate were similar in the renal stone
and non-specific groups, but patients with renal stones were
younger, with higher GFR (renal mass), allowing maximal
production of 1 ,25(OH)2D3 and hence abnormally high
I ,25(OH)2D3 circulating levels. Patients with non-specific
symptoms were older, with lower GFR, which limited the
production of 1 ,25(OH)2D3 and hence its circulating levels. The
reasons for the discrepancy between our results and those of
Broadus et al are not apparent. It may have resulted from the
differences in classification schemes in the two studies, inas-
much as the sex distribution was different. In Broadus's study
there was a female preponderance in the absorptive group and
a male preponderance in the non-absorptive group. In our study
the two sexes were equally affected in the stone—forming group,
and there was a female preponderance in the non-stone—form-
ing, in agreement with other studies [5, 26]. However, when we
used the same classification as Broadus, the sex distribution
was not substantially affected, and we still observed differences
in renal mass and age, as well as in serum 1,25(OH)2D1 (Table
3). Moreover, it should be noted that he Broadus's series
comprised only 50 patients, compared to our 102 patients
representative of a larger population of 306 patients. In addition
in the study of Broadus the difference in mean age between the
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groups was only six years, against 18 years in our study. Thus
the correlation between serum 1 ,25(OH)2D3 and age or GFR
might have been easier to evidence in our study.
Moreover that the circulating levels of l,25(OH)2D3 are
higher in patients with renal stones was not found in two other
studies [5, 6]. In one study, the serum l,25(OH)2D3 was
measured in patients receiving a low calcium diet for three
days, which might have stimulated per se the renal production
of the hormone [27], and thus attenuated potential differences
between patients with and without renal stones. In the second
study, the circulating levels of 1 ,25(OH)2D3 cannot be strictly
compared to those of Broadus's study and ours since the
population of patients was not defined and the circulating levels
of I ,25(OH)2D3 were surprisingly not correlated with intestinal
absorption of calcium.
For the bone disease presentation of PHPT, we confirm here
that the degree of PTH hypersecretion is much higher than in
the other presentations [26, 28, 29]. In addition, we reported
here the first systematic study of circulating levels of
1 ,25(OH)2D3 and intestinal absorption of calcium. We found
low—normal values for circulating l,25(OH)2D3, and low intes-
tinal absorption of calcium. The abnormally—low net calcium
intestinal absorption in the presence of low—normal
l,25(OH),D3 might be partly due to an increase in the
blood—to—lumen flux of calcium caused by hypercalcemia. That
circulating 1 ,25(OH)2D3 was lower in the bone disease presen-
tation than in the non-specific form is not explained by a lower
renal mass in the former. Neither do the higher value of PTH
activity and lower serum phosphorus explain the lower
1,25(OH)2D3 we observed in the bone disease form. In the
present work, the factor limiting kidney 1 ,25(OH)2D3 produc-
tion was likely the very low reserve of vitamin D, as shown by
the abnormally low level of circulating 25(OH)D. The role of the
low values of 25(OH)D as a factor limiting the production of
1,25(OH)2D3 by the kidney is strongly supported by the obser-
vation of the linear positive correlation between serum
25(OH)D and l,25(OH)2D3 in the bone disease group, which
contrasts with the absence of correlation between these varia-
bles in the two other groups of patients. The reason for this very
low 25(OH)D value is not immediately apparent. One possibil-
ity could be that the bone disease presentation of PHPT
represents an initially severe form involving very high degree of
PTH hypersecretion and then a high rate of 25(OH)D conver-
sion to 1 ,25(OH)2D3, which eventually consumes the substrate.
However, the absence of negative correlation between serum
iPTH or NcAMP and serum 25(OH)D in the whole population
does not support this hypothesis. A more likely explanation for
the lower serum 1 ,25(OH)2D3 in the bone disease group is the
association of an initially low reserve of vitamin D with a
common form of PHPT. This possibility was supported by the
malabsorption observed in one patient, and the poor nutritional
and conditional factors in other patients. These eight patients
were women (four immigrants from North Mrica) whose esti-
mated vitamin D intake had been very low and who had not
been exposed to sunlight for a long time (they stayed at home
the whole time). Moreover, the far higher degree of PTH
hypersecretion observed in the bone disease form than in the
other forms cannot be accounted for by differences in plasma
calcium concentrations. We suggest that the dramatically high
hypersecretion of PTH in PHPT with bone disease might be
attributable to the presence of low—normal levels of circulating
I ,25(OH)2D3, which would not limit PTH hypersecretion as it
might in the renal stone or non-specific forms of PHPT, where
1 ,25(OH)2D3 levels were higher than normal. This hypothesis is
plausible since the hypersecretion of PTH is known to be at
least partly suppressible in PHPT [30]. Several findings support
the possibility that 1 ,25(OH)2D3 directly inhibits PTH secretion.
In reports of isolated cases of PHPT with hypercalcemia
combined with vitamin D deficiency, hypersecretion of PTH
diminished after repletion with vitamin D, without significant
increase in calcemia [7]. In primary culture of bovine parathy-
roid cells, addition of 1,25(OH)2D3 was recently shown to
inhibit PTH secretion after 48 hours [31]. Lastly, intravenous
administration of l,25(OH)2D3 to patients with chronic renal
failure was shown to decrease serum iPTH, independent of
changes in serum calcium [32].
In conclusion, we suggest that primary hyperparathyroidism
may be a single entity, and renal mass and reserve of vitamin D
may play a major role in the clinical presentation of the disease.
In young patients with high renal mass and a normal reserve of
vitamin D, chronic hypersecretion of PTH may result in abnor-
mally high serum 1 ,25(OH)2D3, with high intestinal absorption
of calcium, hypercalciuria and a high risk of renal stones. In
older subjects with a lower renal mass, and a normal reserve of
vitamin D, a similar degree of chronic hypersecretion may
result in moderately elevated serum 1 ,25(OH)2D3 and normal
intestinal absorption of calcium, with a low risk of renal stones.
In these two groups, the high circulating 1,25(OH)2D3 levels
might limit directly the hypersecretion of PTH. In older sub-
jects with lower renal mass and vitamin D deficiency,
1 ,25(OH)2D3 levels were low—normal despite the higher hyper-
secretion of PTH. Their low intestinal absorption of Ca, high
bone resorption secondary to far higher hypersecretion of PTH
and very low value of serum phosphorus [331 may account for
a negative calcium balance and may thus explain the bone
disease in PHPT. The higher degree of PTH hypersecretion in
the bone disease presentation might stem from the absence of
direct inhibition of PTH hypersecretion by low—normal circu-
lating 1 ,25(OH)2D3, but this possibility requires further investi-
gation.
Appendix
Abbreviations used in this paper are: 25(OH)D, 25 hydroxy-
vitamin D; 1 ,25(OH)2D3, 1,25 dihydroxyvitamin D3; NcAMP,
nephrogenous cyclic AMP; iPTH, immunoreactive PTH (C
terminal fragment); PHPT, primary hyperparathyroidism;
GFR, glomerular filtration rate; TmPi, inorganic phosphorus
Tm expressed per liter GF.
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